Healthcare company Singlera Genomics, which is a non-invasive genetic testing company, announced that it has successfully raised US$20 million in a Series A financing. The leading financing was done by Lilly Asia Ventures, together with Green Pine Capital Partners, CDBI Partners and others, according to a report in PR Newswire
Based in La Jolla and Shanghai, Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics, according to Crunchbase. Singlera’s main products and medical services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis and others.
Singlera is dedicated to the development of precision medicine, for patients, in the form of early, accurate and informative diagnoses.
The funding will enable Singlera in expansion of the development and commercialization of its non-invasive genomic sequencing tests for cancer and other genetic diseases. Singlera will also use the funds to further expand its R&D operations and enable the launch of new product lines that address tumor diagnosis and give personalized treatment.
Professor Yuan Gao, Chairman of Singlera Genomics, said, “Singlera’s non-invasive genomic sequencing diagnostic technologies could significantly enhance the accuracy of tumor diagnosis and provide powerful guidance for the new treatments. This new funding is a strong vote of confidence in our technologies, scientific research and commercial operations from a group of highly respected healthcare investors”.